{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:08:49Z","timestamp":1792058929682,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC0868700"],"award-info":[{"award-number":["2022YFC0868700"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eclinm.2023.102189","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:07:06Z","timestamp":1693508826000},"page":"102189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial"],"prefix":"10.1016","volume":"63","author":[{"given":"Bei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-mi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-fei","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-huan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-na","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-shan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102189_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajpath.2022.01.007","article-title":"Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with Coronavirus disease 2019 caused by the omicron variant of severe acute Respiratory syndrome Coronavirus 2 in Houston, Texas","volume":"192","author":"Christensen","year":"2022","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eclinm.2023.102189_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.eclinm.2023.102189_bib3","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS:crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J"},{"issue":"15","key":"10.1016\/j.eclinm.2023.102189_bib4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102189_bib5","series-title":"Emergency use authorization 105","year":"2021"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102189_bib6","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients [published correction appears in clin Infect Dis. 2023 mar 01:]","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102189_bib7","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.06283-11","article-title":"Pharmacokinetic\/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors","volume":"56","author":"Reddy","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eclinm.2023.102189_bib8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102189_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J\u00a0Med Virol"},{"issue":"6557","key":"10.1016\/j.eclinm.2023.102189_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102189_bib12","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1080\/07391102.2020.1758791","article-title":"Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes","volume":"39","author":"Elmezayen","year":"2020","journal-title":"J\u00a0Biomol Struct Dyn"},{"key":"10.1016\/j.eclinm.2023.102189_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100794","article-title":"An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment","volume":"59","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"17","key":"10.1016\/j.eclinm.2023.102189_bib14","doi-asserted-by":"crossref","first-page":"9124","DOI":"10.3390\/ijms22179124","article-title":"Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations","volume":"22","author":"Ahmad","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2023.102189_bib16","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"COVID-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"Br Med J"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102189_bib17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMc2205944","article-title":"Nirmatrelvir-ritonavir and viral load rebound in Covid-19","volume":"387","author":"Anderson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102189_bib18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMc2205944","article-title":"EPIC-HR trial investigators. Nirmatrelvir-ritonavir and viral load rebound in Covid-19","volume":"387","author":"Anderson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102189_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","article-title":"Liver injury in COVID-19: management and challenges","volume":"5","author":"Zhang","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2023.102189_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jvh.13590","article-title":"COVID-19 and the liver: lessons learnt from the EAST and the WEST, A year later","volume":"29","author":"Ekpanyapong","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102189_bib21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3390\/v15020384","article-title":"Molnupiravir and nirmatrelvir\/ritonavir: tolerability, safety, and adherence in a retrospective cohort study","volume":"15","author":"Mazzitelli","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102189_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ohn.278","article-title":"Postmarketing reporting of paxlovid-related dysgeusia: a real-world pharmacovigilance study [published online ahead of print, 2023 Feb 5]","volume":"169","author":"Cvancara","year":"2023","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.eclinm.2023.102189_bib23","article-title":"Understanding the risk of drug interactions between ritonavir-containing COVID-19 therapies and small-molecule kinase inhibitors in patients with cancer","volume":"7","author":"Hopkins","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102189_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MS9.0000000000000169","article-title":"Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant","volume":"85","author":"Imran","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.eclinm.2023.102189_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1515\/dx-2020-0046","article-title":"Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States","volume":"7","author":"Aggarwal","year":"2020","journal-title":"Diagnosis (Berl)"},{"key":"10.1016\/j.eclinm.2023.102189_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nefro.2020.05.004","article-title":"Syndrome of inappropriate antidiuretic hormone as the initial presentation of COVID-19: a novel case report","volume":"41","author":"Ho","year":"2021","journal-title":"Nefrologia"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:22:00Z","timestamp":1762899720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023003668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"alternative-id":["S2589537023003668"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102189","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102189"}}